Clinical Trials Logo

Growth Hormone Deficiency clinical trials

View clinical trials related to Growth Hormone Deficiency.

Filter by:

NCT ID: NCT06294860 Recruiting - Clinical trials for Growth Hormone Deficiency

Biological Age in Children With GH Deficiency Undergoing Hormone Replacement Therapy

ETABIOGHD
Start date: June 19, 2023
Phase:
Study type: Observational

The primary objective of the study is to evaluate the epigenetic age in children with GH deficiency, before and after 6 months of treatment with growth hormone replacement therapy. The secondary objective is to correlate the epigenetic age with the auxometric and biochemical parameters used in the clinical-endocrinological practice. The results of the study will be useful to set up the clinical and biochemical follow-up of the hormone replacement therapy with rhGH and to understand the biomolecular mechanisms at the base of the debated "anti" or "pro" aging action of GH, the most important anabolic hormone of the human organism.

NCT ID: NCT05820672 Recruiting - Clinical trials for Growth Hormone Deficiency

A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA

SkybriGHt
Start date: March 20, 2023
Phase:
Study type: Observational [Patient Registry]

The goal of this study is to genrate evidence on long-term effectiveness and safety of SKYTROFA (lonapegsomatropin) in patients with growth hormone deficiency under routine clinical care

NCT ID: NCT05796440 Enrolling by invitation - Clinical trials for Growth Hormone Deficiency

A Long-Term Safety Trial of LUM-201 in Children With Idiopathic Growth Hormone Deficiency Who Have Previously Completed a LUM-201 Clinical Trial (OraGrowtH211)

OraGrowtH211
Start date: August 1, 2023
Phase: Phase 2
Study type: Interventional

This is a multi-national trial. The trial aims to study the long-term safety of LUM-201 in subjects with Idiopathic Pediatric Growth Hormone Deficiency (iPGHD). This study will also assess pharmacodynamics and efficacy response to therapy with LUM-201.

NCT ID: NCT05775523 Recruiting - Clinical trials for Growth Hormone Deficiency

A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin

SkyPASS
Start date: March 20, 2023
Phase:
Study type: Observational

The goal of this study is to further characterise the potential long-term safety risks of lonapegsomatropin in patients treated with lonapegsomatropin under real-world conditions in the post-marketing setting.

NCT ID: NCT05681299 Recruiting - Healthy Clinical Trials

Effects of GH and Lirglutide on AgRP

Start date: May 1, 2023
Phase: Phase 4
Study type: Interventional

This is a randomized, placebo-controlled, cross-over study with 4 arms. Healthy and GH deficient adults ages 18-45 years will be studied. Arms will consist of 21-day treatment periods and be separated by 8-week washout periods. Subjects will receive, in random order: i) GH alone, ii) GH with liraglutide, iii) liraglutide alone and iv) placebo. Each phase of the study will consist of a 7-day baseline period including 2 days of testing and 21 days on therapy with visits on days 2, 7, 14 and 21. Testing before, during and at the completion of each arm will include blood sampling and assessments of insulin resistance, energy expenditure and body composition.

NCT ID: NCT05660356 Not yet recruiting - Clinical trials for Growth Hormone Deficiency

Growth Hormone Deficiency in Mild Traumatic Brain Injury

Start date: February 2023
Phase: Early Phase 1
Study type: Interventional

The goal of this randomized control trial is to test if growth hormone therapy is a safe and effective treatment for patients suffering from growth hormone deficiency and persistent post-concussion symptoms. The main questions it aims to answer are: 1. Is growth hormone therapy effective at mitigating persisting post-concussion symptoms in patients with growth hormone deficiency? 2. Is it feasible to conduct a larger trial to examine efficacy of growth hormone therapy in patients with persistent post-concussion symptoms and growth hormone deficiency? Participants will be asked to complete an initial assessment for study inclusion and to complete clinical outcome questionnaires. If a participant meets study criteria they will be randomized to receive either growth hormone therapy (provided by Pfizer) or a placebo (provided by Pfizer). Participants will be instructed on how to self-administer their assigned drug daily for three months. Monthly follow-up visits will include a blood draw to measure a biomarker and clinical outcome questionnaires. At the final follow-up visit after three months, participants will learn what group they were assigned and given the option to complete the growth hormone therapy if they were originally assigned to the placebo group. Researchers will compare the growth hormone therapy group to the placebo group to identify any potential differences in outcomes.

NCT ID: NCT05645211 Not yet recruiting - Clinical trials for Growth Hormone Deficiency

The AgRP and GH/IGF-1 Axis in Children

Start date: January 1, 2023
Phase:
Study type: Observational

Recent data support the existence of a GH-Agouti-related peptide (AgRP) axis. The neuropeptide AgRP promotes food intake and has important effects on energy homeostasis. Recent evidence suggest that GH stimulates AgRP and AgRP may mediate some of GH's important nutritional and metabolic effects. main goals of this project are to characterize, for the first time, plasma levels of AgRP in children and to determine how these relate to GH and IGF-1 levels, age, body composition, clinical and other endocrine parameters. To accomplish this, we will conduct two studies, one being a cross-sectional study that will measure AgRP levels in 140 healthy children ages 5-17 and the second being a prospective study that will measure the change in plasma AgRP levels in response to GH treatment in 16 children who receive this as part of their clinical care for GH deficiency or short stature.

NCT ID: NCT05603936 Recruiting - Clinical trials for Growth Hormone Deficiency

Adaption and Testing of the Quality of Life in Short Stature Youth (QoLISSY) Questionnaire for Parents With Children From 0-4

Start date: March 1, 2022
Phase:
Study type: Observational

The aim of the study is the adaption, implementation and validation of the instrument for the investigation of the short stature specific quality of life (QoLISSY) for children (age 0-4 years) with achondroplasia (ACH), Small for Gestational Age (SGA) and Growth Hormone Deficiency (GHD) from a parental perspective.

NCT ID: NCT05448924 Completed - Clinical trials for Growth Hormone Deficiency

Isolated Growth Hormone Deficiency and Amennorrhea

Start date: December 1, 2021
Phase:
Study type: Observational

This is a case report of a 14-year old female with no menstruation history.

NCT ID: NCT05250063 Active, not recruiting - Clinical trials for Growth Hormone Deficiency

Phase 2 Study of LUM-201 in Children Who Have Previously Completed the LUM-201-01 Trial (OraGrowtH213)

OraGrowtH213
Start date: February 18, 2022
Phase: Phase 2
Study type: Interventional

This is a multi-national trial. The goals of the trial are to study the growth response to LUM-201 administration in children with idiopathic growth hormone deficiency (GHD) previously treated with daily rhGH for 12 months in the LUM-201-01 trial.